JP Morgan initiated coverage on Cepheid CPHD with an Overweight rating and a $47 price target.
JP Morgan noted, "As an early leader in the rapidly-growing molecular diagnostics industry, CPHD already has a large commercial installed base of >2,650 of its GeneXpert systems, which can run any of the company's expanding menu of diagnostic tests; the company has 11 FDA-cleared tests available (14 internationally), a number set to grow to ~25 by 2015, while expanding the addressable market by >$1B. After evaluating competitive offerings, including through a proprietary lab survey, we are confident that the company's market leadership is sustainable."
Cepheid closed at $38.95 on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in